OrbusNeich Medical Group Holdings Limited
3.73
HKD
-0.05
(-1.32%)
ISIN
KYG6773B1005
CUSIP
G6773B100
Return %
Stock
S&P 500
1Y
-17.84
14.20
3Y
-59.37
81.12
5Y
- -
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- David Chien
- Full Time Employees
- 1,477
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Building 20E Hong Kong Hong Kong
- IPO Date
- Dec 23, 2022
- Website
- orbusneich.com
- Similar Companies
- Business
- OrbusNeich Medical Group Holdings Limited (6929.HK) is an investment holding company engaged in the design, development, manufacture, distribution and sale of interventional medical devices for the treatment of coronary heart disease and peripheral vascular diseases; its core products include percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) balloons, semi-compliant balloons and scoring balloons such as Scoreflex NC for pre-dilatation and lesion preparation, coronary stents including the COMBO Plus dual therapy stent and drug-eluting stents for implantation, non-compliant balloons such as JADE for post-dilatation, specialty catheters, drug-coated balloons, microcatheters, guide catheter extensions, self-expandable stent systems and products for neurovascular intervention and structural heart disease. Founded in 2000 and headquartered in Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong, the company operates manufacturing facilities in Shenzhen, China and the Netherlands, with sales in over 70 countries including Japan, Europe, the Middle East, Africa, Asia-Pacific, China and the United States through direct sales teams and distributors. OrbusNeich Medical Group Holdings Limited, a subsidiary of Harmony Tree Limited, listed on the Hong Kong Stock Exchange in 2022 and employs approximately 1,430 people. In recent developments, the company advanced clinical trials for the TricValve Bicaval Valves System through its joint venture OrbusNeich P&F by expanding participating sites from 13 to 21 in China and gaining access in the Greater Bay Area as of 2025; it acquired a distributor in Taiwan in the first half of 2025 and plans direct sales teams in Belgium and the Netherlands in the second half; additionally, it expanded an exclusive distribution partnership with Shenzhen Chieway Medical Technology Co., Ltd. for intravascular ultrasound products to Singapore, Malaysia, four European direct markets (France, Germany, Spain, Switzerland) and six distributor markets following the initial Hong Kong and Macau agreement.